Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Italy Fines Apple €98.6 Million Over App Store Dominance 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
PARSIPPANY, N.J., July 25, 2017 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results before the open of the U.S. markets on Wednesday, August 2, 2017. The announcement will be followed by a conference call at 8:30 a.m. ET. Participating in the call from Pacira will be Dave Stack, chairman and chief executive officer, and other members of the company’s senior management team.
The call can be accessed by dialing 1-877-845-0779 (domestic) or 1-720-545-0035 (international) ten minutes prior to the start of the call and providing the Conference ID 46683453. A replay of the call will be available approximately two hours after the completion of the call and can be accessed by dialing 1-855-859-2056 (domestic) or 1-404-537-3406 (international) and providing the Conference ID 46683453. The replay of the call will be available for one week from the date of the live call.
The live, listen-only webcast of the conference call can also be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the call.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.
Investor Contact: Pacira Pharmaceuticals, Inc. Susan Mesco, (973) 451-4030 [email protected]
